Argonaut Manufacturing Services Appoints J.D. Mowery to Board of Directors
Argonaut Manufacturing Services (Argonaut), a U.S.-based contract development and manufacturing organization (CDMO) specializing in sterile fill-finish services for injectable biologics and pharmaceutical products, has announced the appointment of J.D. Mowery to its Board of Directors. The addition strengthens Argonaut’s leadership and governance team with an executive who brings more than two decades of experience spanning biopharmaceutical manufacturing, CDMO operations, biotechnology, and commercial-scale production.
Mowery’s appointment comes as Argonaut continues to expand its capabilities as a manufacturing partner for pharmaceutical and biotechnology companies developing injectable therapies. His experience across both innovator organizations and contract manufacturing businesses is expected to provide additional strategic and operational perspective as Argonaut supports customers through different stages of the product lifecycle, from clinical development through commercial manufacturing.
Mowery has built a career around biopharmaceutical operations, manufacturing strategy, business growth, and the development of complex production capabilities. Most recently, he served as President of the global CDMO division at Bora Pharmaceuticals, where he was responsible for strategy, commercial growth, and operations across a multi-site manufacturing network spanning North America and Asia.
In that role, Mowery worked across a geographically diverse manufacturing organization and focused on strengthening operational capabilities while supporting the growth of the company’s CDMO business. His experience leading manufacturing operations across multiple markets adds to the range of expertise represented on Argonaut’s Board of Directors.
Before joining Bora Pharmaceuticals, Mowery served as President and Chief Executive Officer of KBI Biopharma. He also served as an Officer of KBI Biopharma’s parent company, JSR Corporation. During his tenure in senior leadership, he gained extensive experience working at the intersection of biotechnology development, manufacturing, and commercial strategy.
His professional background also includes senior operational leadership roles at AGC Biologics, Juno Therapeutics, and Lonza. Across these organizations, Mowery worked with a broad range of biopharmaceutical technologies and manufacturing platforms, including biologics, cell and gene therapies, and aseptic manufacturing.
That experience has included leading organizations through periods of operational expansion, increasing manufacturing capacity, supporting commercialization efforts, and helping advance complex therapeutic programs from clinical development into commercial production. Such experience is particularly relevant to CDMOs, which must balance the manufacturing requirements of emerging clinical programs with the quality, reliability, scalability, and regulatory expectations associated with commercial pharmaceutical production.
Argonaut said Mowery’s combination of experience with innovative biopharmaceutical companies and CDMOs will provide valuable insight as the organization continues to develop its manufacturing capabilities and serve customers across the development lifecycle.
“J.D.’s experience with both innovator companies and CDMOs brings valuable perspective and operational expertise to Argonaut’s board,” said Alex Herzick, Board Member at Argonaut Manufacturing Services. “He will be an excellent complement to our talented management team and further strengthen the company’s position as a leading, customer- and quality-focused sterile fill-finish partner.”
Expanding Expertise in Sterile Fill-Finish Manufacturing
Sterile fill-finish represents an important stage in the production of injectable medicines, requiring specialized manufacturing infrastructure, rigorous quality systems, and processes designed to maintain product sterility and integrity. For biotechnology and pharmaceutical companies, access to reliable fill-finish capacity can be an important component of moving drug candidates from development and clinical studies toward broader manufacturing and commercialization.
Argonaut operates within this segment as a U.S.-based CDMO focused on sterile fill-finish services for injectable biologics and pharmaceuticals. Its work supports customers that require manufacturing expertise and production capabilities for programs at different stages of development.
Mowery’s career in biologics manufacturing and aseptic operations gives him direct experience with many of the challenges associated with this environment. His leadership background includes capacity expansion, operational scale-up, manufacturing excellence, commercialization, and technology adoption.
As pharmaceutical pipelines become increasingly diverse, CDMOs are also being asked to support more complex manufacturing requirements. Biologics, cell and gene therapies, and other advanced treatments can require specialized processes, carefully controlled production environments, and manufacturing strategies that can evolve as programs advance through clinical development.
Mowery’s experience across these areas provides a broad perspective that can be applied to Argonaut’s ongoing growth strategy. His background also includes experience working with companies at different points in the pharmaceutical and biotechnology value chain, allowing him to bring an understanding of both customer expectations and manufacturing operations to the boardroom.
Experience Across Manufacturing and Biotechnology
Throughout his career, Mowery has held leadership positions involving operational performance, strategic planning, commercial development, and organizational growth. His work at companies including KBI Biopharma, AGC Biologics, Juno Therapeutics, Lonza, and Bora Pharmaceuticals has exposed him to multiple aspects of the biopharmaceutical manufacturing ecosystem.
His experience with KBI Biopharma is particularly relevant to his new role at Argonaut. During his time leading KBI, Mowery helped establish a strategic alliance with Argonaut, giving him an opportunity to become familiar with the company, its team, and its approach to manufacturing partnerships.
Mowery also currently serves in board and advisory positions with organizations involved in areas including aseptic manufacturing, life sciences infrastructure, automation, artificial intelligence, and biotechnology. These roles have broadened his exposure to technologies and business models that are influencing the pharmaceutical manufacturing industry.
His advisory experience includes areas such as strategic growth, operational scaling, manufacturing excellence, and technology adoption. These capabilities could support Argonaut as it evaluates opportunities to expand its capabilities and strengthen its position within the sterile fill-finish market.
Supporting Customers From Clinical Development Through Commercial Manufacturing
For pharmaceutical and biotechnology companies, manufacturing requirements can change significantly as a therapeutic program progresses. Early-stage programs may require smaller-scale production and flexible support, while later-stage and commercial programs can require greater capacity, consistent processes, supply reliability, and scalable infrastructure.
A CDMO that can support customers across these stages can play an important role in helping development programs progress toward commercialization. Argonaut’s focus on sterile fill-finish positions the company within a critical part of the injectable drug manufacturing process.
Mowery’s background in guiding manufacturing organizations through growth and commercialization aligns with this development-to-commercial pathway. His experience includes helping organizations expand capacity and operational capabilities while supporting complex therapies as they move toward larger-scale manufacturing.
In his comments on joining Argonaut’s board, Mowery highlighted his previous relationship with the company and his confidence in its people and manufacturing capacity.
“When I led KBI, I helped establish a strategic alliance with Argonaut and came to know the quality and commitment of its team,” said Mowery. “Argonaut has the people and capacity to help development programs move forward today, while building a lasting impact for patients. I believe there is real power in Argonaut, Telegraph Hill Partners, and NewVale Capital working together toward that goal. I’m honored to join a board with such depth of experience and contribute to the work ahead.”
Strengthening Argonaut’s Leadership Platform
Mowery’s appointment adds another layer of manufacturing and biotechnology expertise to Argonaut’s Board of Directors. His experience across CDMO operations, innovator companies, aseptic manufacturing, advanced therapies, and technology adoption provides a broad foundation for contributing to the company’s strategic direction.
The appointment also reflects the importance of experienced manufacturing leadership as pharmaceutical companies increasingly rely on specialized external partners to support development and production. CDMOs must maintain high standards for quality and operational execution while adapting to evolving customer requirements and increasingly sophisticated therapeutic modalities.
For Argonaut, Mowery’s experience is expected to complement the company’s management team as it continues to develop its sterile fill-finish capabilities and work with customers across clinical and commercial manufacturing programs.
His previous relationship with Argonaut through KBI Biopharma also provides continuity, allowing him to join the Board with an existing understanding of the organization and its team. Combined with his more recent experience leading a global CDMO division, his appointment brings perspectives from both sides of the biopharmaceutical manufacturing relationship.
With Mowery joining its Board of Directors, Argonaut is adding an executive with extensive experience in manufacturing strategy, operational growth, commercial development, and biotechnology. The appointment is positioned to support the company’s continued efforts to expand its capabilities while maintaining a focus on quality, customer needs, and reliable sterile manufacturing services for injectable therapies.
About Argonaut Manufacturing Services
Argonaut is a California-based CDMO specializing in clinical through commercial aseptic fill-finish for injectable biologics and pharmaceuticals. Argonaut’s filling capabilities support vials, prefilled syringes, and cartridges and uses high-yield processes and 100% non-destructive weight verification to minimize line loss. Its two isolator-based filling lines provide advanced contamination control and sterility assurance in compliance with global regulatory standards, including EU Annex 1. Argonaut also provides onsite analytical support and stability studies.